Abstract
Objective To analyze the effects of treatment with Zoledronic acid on the characteristics of bone metabolism in elderly people with osteoporotic fractures versus osteoarthritis. Methods The 105 patients treated with Zoledronic acid (54 osteoporotic fractures patients, 51 osteoarthritis patients) were retrospectively analyzed from May 2013 to November 2014. The serum levels of total procollagen type 1 amino-terminal propeptide (tP1NP), N-MID osteocalcin (OCN), and β-crossLaps (β-CTX) were measured by ECLIA in all patients before and 1 week and 1 year after the treatment. Bone mineral density (BMD) was measured by dual-energy X-ray densitometer (DXA) before and 1 year after the treatment. Results One week after treatment, tP1NP level were increased in osteoporotic fractures patients (P 0.05). Conclusions The treatment of Zoledronic acid can decrease bone metabolism in elderly people of orthopaedics effectively, especially in osteoporotic fractures patients through inhibiting bone resorption, and can improve BMD in lumber significantly. Key words: Phosphonic acid; Osteoporosis; Fractures, bone; Osteoarthritis
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
